Cleveland BioLabs (CBLI) Rating Lowered to Sell at ValuEngine

Cleveland BioLabs (NASDAQ:CBLI) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Shares of Cleveland BioLabs (CBLI) traded up $0.16 on Friday, hitting $2.59. The stock had a trading volume of 47,558 shares, compared to its average volume of 26,222. Cleveland BioLabs has a 1 year low of $1.22 and a 1 year high of $5.55.

Cleveland BioLabs (NASDAQ:CBLI) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) EPS for the quarter. The company had revenue of $0.30 million during the quarter. Cleveland BioLabs had a negative return on equity of 91.87% and a negative net margin of 472.44%.

A hedge fund recently raised its stake in Cleveland BioLabs stock. Virtu KCG Holdings LLC boosted its holdings in shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 275.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,091 shares of the biotechnology company’s stock after purchasing an additional 38,233 shares during the quarter. Virtu KCG Holdings LLC owned approximately 0.46% of Cleveland BioLabs worth $154,000 at the end of the most recent reporting period. 4.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Cleveland BioLabs (CBLI) Rating Lowered to Sell at ValuEngine” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with's FREE daily email newsletter.

Leave a Reply